HealthQuill Adverse events
Pfizer Inc., has discontinued its clinical trials of the twice-daily oral weight-loss drug, danuglipron, after more than 50% of the patients opted out due to adverse effects of the medicine.
Drugs Health Pharma

Pfizer Inc., stops twice-daily oral obesity drug trial at mid-stage

HQ Team December 2, 2023: Pfizer Inc., has discontinued its clinical trials of the twice-daily oral weight-loss drug, danuglipron, after more than 50%.

Read More
The FDA has warned consumers against the use of fast-act rheum and UA-Block capsules used to treat inflammation and joint pains as it contains substances that raise blood sugar, heart attacks, and stroke.
Drugs Health Medical Pharma

FDA warns against use of Fast-act and UA-Block capsules to treat rheumatism

HQ Team May 11, 2023: The FDA has warned consumers against using fast-act rheum and UA-Block capsules to treat inflammation and joint pains.

Read More
X